Cargando…

Long-term outcome of cutaneous melanoma patients treated with boron neutron capture therapy (BNCT)

Our aim was to assess the long-term clinical outcome of boron neutron capture therapy (BNCT) using (10)B-para-boronophenylalanine (BPA) as the boron delivery agent for cutaneous melanoma. Eight patients (eight lesions) were treated between October 2003 and April 2014. Their ages ranged from 48 to 86...

Descripción completa

Detalles Bibliográficos
Autores principales: Hiratsuka, Junichi, Kamitani, Nobuhiko, Tanaka, Ryo, Tokiya, Ryoji, Yoden, Eisaku, Sakurai, Yosinori, Suzuki, Minoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7674695/
https://www.ncbi.nlm.nih.gov/pubmed/32990318
http://dx.doi.org/10.1093/jrr/rraa068
_version_ 1783611559378944000
author Hiratsuka, Junichi
Kamitani, Nobuhiko
Tanaka, Ryo
Tokiya, Ryoji
Yoden, Eisaku
Sakurai, Yosinori
Suzuki, Minoru
author_facet Hiratsuka, Junichi
Kamitani, Nobuhiko
Tanaka, Ryo
Tokiya, Ryoji
Yoden, Eisaku
Sakurai, Yosinori
Suzuki, Minoru
author_sort Hiratsuka, Junichi
collection PubMed
description Our aim was to assess the long-term clinical outcome of boron neutron capture therapy (BNCT) using (10)B-para-boronophenylalanine (BPA) as the boron delivery agent for cutaneous melanoma. Eight patients (eight lesions) were treated between October 2003 and April 2014. Their ages ranged from 48 to 86 years at the time of treatment. All of the targets were primary lesions and they were located on the sole or face. No patient had evidence of regional lymph node involvement, distant metastases or an active secondary cancer. The clinical stage was cT1-2N0M0 and performance scores were <2. BNCT was carried out at the Kyoto University Research Reactor (KUR). The patients were irradiated with an epithermal neutron beam between the curative tumor dose and the tolerable skin dose. Eight patients were evaluated and six showed a complete response (CR), while two patients had a partial response (PR). Of the two patients with a PR, one has remained a PR with brown spots persisting for 7.5 years following BNCT. The tumor in the other patient recurred after 6 years at the site of persisting brown macula. The overall control rate (CR + PR without recurrence) for the cohort was 88% (7/8). There have never been any adverse events >Grade 2 for the long follow-up period. Our results suggest that BNCT may be a promising treatment modality in the management of early stage cutaneous melanoma when wide local excision is not feasible.
format Online
Article
Text
id pubmed-7674695
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-76746952020-11-24 Long-term outcome of cutaneous melanoma patients treated with boron neutron capture therapy (BNCT) Hiratsuka, Junichi Kamitani, Nobuhiko Tanaka, Ryo Tokiya, Ryoji Yoden, Eisaku Sakurai, Yosinori Suzuki, Minoru J Radiat Res Oncology/Medicine Our aim was to assess the long-term clinical outcome of boron neutron capture therapy (BNCT) using (10)B-para-boronophenylalanine (BPA) as the boron delivery agent for cutaneous melanoma. Eight patients (eight lesions) were treated between October 2003 and April 2014. Their ages ranged from 48 to 86 years at the time of treatment. All of the targets were primary lesions and they were located on the sole or face. No patient had evidence of regional lymph node involvement, distant metastases or an active secondary cancer. The clinical stage was cT1-2N0M0 and performance scores were <2. BNCT was carried out at the Kyoto University Research Reactor (KUR). The patients were irradiated with an epithermal neutron beam between the curative tumor dose and the tolerable skin dose. Eight patients were evaluated and six showed a complete response (CR), while two patients had a partial response (PR). Of the two patients with a PR, one has remained a PR with brown spots persisting for 7.5 years following BNCT. The tumor in the other patient recurred after 6 years at the site of persisting brown macula. The overall control rate (CR + PR without recurrence) for the cohort was 88% (7/8). There have never been any adverse events >Grade 2 for the long follow-up period. Our results suggest that BNCT may be a promising treatment modality in the management of early stage cutaneous melanoma when wide local excision is not feasible. Oxford University Press 2020-09-29 /pmc/articles/PMC7674695/ /pubmed/32990318 http://dx.doi.org/10.1093/jrr/rraa068 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of The Japanese Radiation Research Society and Japanese Society for Radiation Oncology. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Oncology/Medicine
Hiratsuka, Junichi
Kamitani, Nobuhiko
Tanaka, Ryo
Tokiya, Ryoji
Yoden, Eisaku
Sakurai, Yosinori
Suzuki, Minoru
Long-term outcome of cutaneous melanoma patients treated with boron neutron capture therapy (BNCT)
title Long-term outcome of cutaneous melanoma patients treated with boron neutron capture therapy (BNCT)
title_full Long-term outcome of cutaneous melanoma patients treated with boron neutron capture therapy (BNCT)
title_fullStr Long-term outcome of cutaneous melanoma patients treated with boron neutron capture therapy (BNCT)
title_full_unstemmed Long-term outcome of cutaneous melanoma patients treated with boron neutron capture therapy (BNCT)
title_short Long-term outcome of cutaneous melanoma patients treated with boron neutron capture therapy (BNCT)
title_sort long-term outcome of cutaneous melanoma patients treated with boron neutron capture therapy (bnct)
topic Oncology/Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7674695/
https://www.ncbi.nlm.nih.gov/pubmed/32990318
http://dx.doi.org/10.1093/jrr/rraa068
work_keys_str_mv AT hiratsukajunichi longtermoutcomeofcutaneousmelanomapatientstreatedwithboronneutroncapturetherapybnct
AT kamitaninobuhiko longtermoutcomeofcutaneousmelanomapatientstreatedwithboronneutroncapturetherapybnct
AT tanakaryo longtermoutcomeofcutaneousmelanomapatientstreatedwithboronneutroncapturetherapybnct
AT tokiyaryoji longtermoutcomeofcutaneousmelanomapatientstreatedwithboronneutroncapturetherapybnct
AT yodeneisaku longtermoutcomeofcutaneousmelanomapatientstreatedwithboronneutroncapturetherapybnct
AT sakuraiyosinori longtermoutcomeofcutaneousmelanomapatientstreatedwithboronneutroncapturetherapybnct
AT suzukiminoru longtermoutcomeofcutaneousmelanomapatientstreatedwithboronneutroncapturetherapybnct